Characterizing ligands for farnesoid X receptor – available in vitro test systems for farnesoid X receptor modulator development

Bibliography

• Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284(5418):1365-8
   PubMed Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284(5418):1362-5
   PubMed Web of Science ®Google Scholar
• Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3(5):543-53
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen W, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res 2008;18(11):1087-95
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Mencarelli A, Distrutti E, et al. Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr Med Chem 2010;17(2):139-59
   PubMed Web of Science ®Google Scholar
• Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010;51(4):771-84
   PubMed Web of Science ®Google Scholar
• Düfer M, Hörth K, Wagner R, et al. Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 2012;61(6):1479-89
   PubMed Web of Science ®Google Scholar
• Düfer M, Hörth K, Krippeit-Drews P, Drews G. The significance of the nuclear farnesoid X receptor (FXR) in β cell function. Islets 2012;4(5):333-8
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006;103(4):1006-11
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yin L, Anderson J, et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem 2010;285(5):3035-43
   PubMedGoogle Scholar
• Renga B, Mencarelli A, Cipriani S, et al. The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PLoS One 2013;8(1):e54472
   PubMed Web of Science ®Google Scholar
• Nijmeijer RM, Gadaleta RM, van Mil SWC, et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One 2011;6(8):e23745
   PubMedGoogle Scholar
• Wildenberg ME, van den Brink GR. FXR activation inhibits inflammation and preserves the intestinal barrier in IBD. Gut 2011;60(4):432-3
   PubMed Web of Science ®Google Scholar
• Wang X, Fu X, van Ness C, et al. Bile acid receptors and liver cancer. Curr Pathobiol Rep 2013;1(1):29-35
   PubMedGoogle Scholar
• Vaquero J, Briz O, Herraez E, et al. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochim Biophys Acta 2013;1833(10):2212-19
   PubMed Web of Science ®Google Scholar
• Merk D, Steinhilber D, Schubert-Zsilavecz M. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators. Future Med Chem 2012;4(8):1015-36
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA): a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45(17):3569-72
   PubMed Web of Science ®Google Scholar
• Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000;43(16):2971-4
   PubMed Web of Science ®Google Scholar
• Downes M, Verdecia MA, Roecker AJ, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003;11(4):1079-92
   PubMed Web of Science ®Google Scholar
• Tsai C, Liang J, Lin H. Sesquiterpenoids from Atractylodes macrocephala act as farnesoid X receptor and progesterone receptor modulators. Bioorgan Med Chem Lett 2012;22(6):2326-9
   PubMed Web of Science ®Google Scholar
• Lundquist JT, Harnish DC, Kim CY, et al. Improvement of physiochemical properties of the tetrahydroazepinoindole series of Farnesoid X Receptor (FXR) agonists: beneficial modulation of lipids in primates. J Med Chem 2010;53(4):1774-87
   PubMed Web of Science ®Google Scholar
• Mehlmann JF, Crawley ML, Lundquist JT, et al. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR). Bioorgan Med Chem Lett 2009;19(18):5289-92
   PubMed Web of Science ®Google Scholar
• Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 2002;30(6):503-12
   PubMed Web of Science ®Google Scholar
• Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002;29(1):23-39
   PubMed Web of Science ®Google Scholar
• Putra MY, Bavestrello G, Cerrano C, et al. Polyhydroxylated sterols from the Indonesian soft coral Sinularia sp. and their effect on farnesoid X-activated receptor. Steroids 2012;77(5):433-40
   PubMed Web of Science ®Google Scholar
• Renga B, Mencarelli A, D'Amore C, et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One 2012;7(1):e30443
   PubMedGoogle Scholar
• Schuster D, Markt P, Grienke U, et al. Pharmacophore-based discovery of FXR agonists. Part I: model development and experimental validation. Bioorgan Med Chem 2011;19(23):7168-80
   PubMed Web of Science ®Google Scholar
• Marinozzi M, Carotti A, Sansone E, et al. Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists. Bioorgan Med Chem 2012;20(11):3429-45
   PubMed Web of Science ®Google Scholar
• Sepe V, Bifulco G, Renga B, et al. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of Farnesoid-X-Receptor. J Med Chem 2011;54(5):1314-20
   PubMed Web of Science ®Google Scholar
• Gioiello A, Macchiarulo A, Carotti A, et al. Extending SAR of bile acids as FXR ligands: Discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine. Bioorgan Med Chem 2011;19(8):2650-8
   PubMed Web of Science ®Google Scholar
• Rizzo G, Passeri D, de Franco F, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual Farnesoid X Receptor and TGR5 agonist. Mol Pharmacol 2010;78(4):617-30
   PubMed Web of Science ®Google Scholar
• de Marino S, Ummarino R, D’Auria MV, et al. 4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. Steroids 2012;77(5):484-95
   PubMed Web of Science ®Google Scholar
• Di Leva FS, Festa C, D’Amore C, et al. Binding mechanism of the Farnesoid X Receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. design, synthesis, and biological evaluation of novel ligands. J Med Chem 2013;56(11):4701-17
   PubMed Web of Science ®Google Scholar
• de Marino S, Ummarino R, D’Auria MV, et al. Theonellasterols and conicasterols from theonella swinhoei. novel marine natural ligands for human nuclear receptors. J Med Chem 2011;54(8):3065-75
   PubMed Web of Science ®Google Scholar
• Grienke U, Mihály-Bison J, Schuster D, et al. Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum. Bioorgan Med Chem 2011;19(22):6779-91
   PubMed Web of Science ®Google Scholar
• Iguchi Y, Kihira K, Nishimaki-Mogami T, Une M. Structure–activity relationship of bile alcohols as human farnesoid X receptor agonist. Steroids 2010;75(1):95-100
   PubMed Web of Science ®Google Scholar
• Hohng S, Lee S, Lee J, Jo MH. Maximizing information content of single-molecule FRET experiments: multi-color FRET and FRET combined with force or torque. Chem Soc Rev 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Li G, Lin W, Araya JJ, et al. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol 2012;258(2):268-74
   PubMed Web of Science ®Google Scholar
• Akwabi-Ameyaw A, Bass JY, Caldwell RD, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: naphthoic acid-based analogs of GW 4064. Bioorgan Med Chem Lett 2008;18(15):4339-43
   PubMed Web of Science ®Google Scholar
• Akwabi-Ameyaw A, Bass JY, Caldwell RD, et al. FXR agonist activity of conformationally constrained analogs of GW 4064. Bioorgan Med Chem Lett 2009;19(16):4733-9
   PubMed Web of Science ®Google Scholar
• Bass JY, Caldwell RD, Caravella JA, et al. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064. Bioorgan Med Chem Lett 2009;19(11):2969-73
   PubMed Web of Science ®Google Scholar
• Bass JY, Caravella JA, Chen L, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorgan Med Chem Lett 2011;21(4):1206-13
   PubMed Web of Science ®Google Scholar
• Abel U, Schlüter T, Schulz A, et al. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorgan Med Chem Lett 2010;20(16):4911-17
   PubMed Web of Science ®Google Scholar
• Urizar NL, A. natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002;296(5573):1703-6
   PubMed Web of Science ®Google Scholar
• Huang H, Yu Y, Gao Z. et al. Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal Farnesoid X Receptor (FXR) selective antagonists. J Med Chem 2012;55(16):7037-53
   PubMed Web of Science ®Google Scholar
• Marinozzi M, Carotti A, Sardella R, et al. Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: role of the chirality on the biological activity. Bioorgan Med Chem 2013;21(13):3780-9
   PubMed Web of Science ®Google Scholar
• Patching SG. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Biochim Biophys Acta 2013; doi: 10.1016/j.bbamem.2013.04.028; Epub ahead of print
   Web of Science ®Google Scholar
• Choi H, Hwang H, Chin J, et al. Tuberatolides, potent FXR antagonists from the korean marine tunicate botryllus tuberatus. J Nat Prod 2011;74(1):90-4
   PubMed Web of Science ®Google Scholar
• Richter HG, Benson GM, Blum D, et al. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorgan Med Chem Lett 2011;21(1):191-4
   PubMed Web of Science ®Google Scholar
• Richter HG, Benson G, Bleicher K, et al. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorgan Med Chem Lett 2011;21(4):1134-40
   PubMed Web of Science ®Google Scholar
• Nichols JS, Parks DJ, Consler TG, Blanchard SG. Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain. Anal Biochem 1998;257(2):112-19
   PubMed Web of Science ®Google Scholar
• Han K, Kim JH, Kim K, et al. Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay. Anal Biochem 2010;398(2):185-90
   PubMed Web of Science ®Google Scholar
• Yu DD, Lin W, Chen T, Forman BM. Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery. Bioorgan Med Chem 2013;21(14):4266-78
   PubMed Web of Science ®Google Scholar
• Kemper JK, Xiao Z, Ponugoti B, et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 2009;10(5):392-404
   PubMed Web of Science ®Google Scholar
• Kemper JK. Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications. Biochim Biophys Acta BBAMol Basis Dis 2011;1812(8):842-50
   PubMed Web of Science ®Google Scholar
• Gineste R, Sirvent A, Paumelle R, et al. Phosphorylation of farnesoid X receptor by protein kinase c promotes its transcriptional activity. Mol Endocrinol 2008;22(11):2433-47
   PubMed Web of Science ®Google Scholar
• Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 2011;477(7365):477-81
   PubMed Web of Science ®Google Scholar
• Sepe V, Ummarino R, D'Auria M, et al. Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge theonella swinhoei. Mar Drugs 2012;10(12):2448-66
   PubMedGoogle Scholar
• Lin H. Identification of liver X receptor and farnesoid X receptor dual agonists from Tithonia diversifolia. Med Chem Res 2013;22(7):3270-81
   Web of Science ®Google Scholar
• Suzuki T, Nishimaki-Mogami T, Kawai H, et al. Screening of novel nuclear receptor agonists by a convenient reporter gene assay system using green fluorescent protein derivatives. Phytomedicine 2006;13(6):401-11
   PubMed Web of Science ®Google Scholar
• Flatt B, Martin R, Wang T, et al. Discovery of XL335 (WAY-362450): a highly potent, selective, and orally active agonist of the Farnesoid X Receptor (FXR). J Med Chem 2009;52(4):904-7
   PubMed Web of Science ®Google Scholar
• Feng S, Yang M, Zhang Z, et al. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorgan Med Chem Lett 2009;19(9):2595-8
   PubMed Web of Science ®Google Scholar
• Soisson SM, Parthasarathy G, Adams AD, et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc Natl Acad Sci USA 2008;105(14):5337-42
   PubMed Web of Science ®Google Scholar